Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 1/2 6Phase 2 5Phase 1 2Phase 2/3 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1

Conditions

Lymphoma, Large-Cell, Anaplastic 1Carcinoma, Hepatocellular 1

Interventions

Specimen Handling 147pembrolizumab 124Magnetic Resonance Spectroscopy 114Cyclophosphamide 114Biopsy 104fludarabine 84Nivolumab 59Carboplatin 54Gemcitabine 46Cisplatin 46venetoclax 45Radiotherapy 45Paclitaxel 43Ipilimumab 38fludarabine phosphate 37Cetuximab 37Fluorouracil 34atezolizumab 31Bevacizumab 31durvalumab 30X-Rays 28Oxaliplatin 28Dexamethasone 28Leucovorin 27Radiation 26Irinotecan 26Azacitidine 25Injections 24Cytarabine 24Radiosurgery 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × alectinib × 90 days × Clear all
NCT07001384 2026-05-26

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Memorial Sloan Kettering Cancer Center

Phase 1 Recruiting
30 enrolled
Lymphoid

Lymphoma, Large-Cell, Anaplastic

NCT06354387 2026-03-19

Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1

China Medical University Hospital

Phase 1 Completed
5 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡